1. Genomic landscape of the immune microenvironments of brain metastases in breast cancer
- Author
-
Jin-jiang Li, Wei-cheng Lu, Hui Xie, Anhua Wu, Ce Yuan, and Zhao-yang Li
- Subjects
0301 basic medicine ,medicine.medical_treatment ,lcsh:Medicine ,Breast Neoplasms ,Gene ,General Biochemistry, Genetics and Molecular Biology ,03 medical and health sciences ,0302 clinical medicine ,Immune system ,Breast cancer ,Gene expression ,medicine ,Tumor Microenvironment ,Humans ,Breast ,Transcription factor ,Survival analysis ,biology ,business.industry ,Brain Neoplasms ,Dock2 ,Research ,lcsh:R ,Brain metastases ,General Medicine ,Immunotherapy ,Genomics ,medicine.disease ,Immune ,030104 developmental biology ,030220 oncology & carcinogenesis ,biology.protein ,Cancer research ,business ,Infiltration (medical) - Abstract
Background This study was intended to investigate the genomic landscape of the immune microenvironments of brain metastases in breast cancer. Methods Three gene expression profile datasets (GSE76714, GSE125989 and GSE43837) of breast cancer with brain metastases were downloaded from Gene Expression Omnibus (GEO) database. After differential expression analysis, the tumor immune microenvironment and immune cell infiltration were analyzed. Then immune-related genes were identified, followed by function analysis, transcription factor (TF)-miRNA–mRNA co-regulatory network analysis, and survival analysis of metastatic recurrence. Results The present results showed that the tumor immune microenvironment in brain metastases was immunosuppressed compared with primary caner. Compared with primary cancer samples, the infiltration ratio of plasma cells in brain metastases samples was significantly higher, while the infiltration ratio of macrophages M2 cells in brain metastases samples was significantly lower. Total 42 immune-related genes were identified, such as THY1 and NEU2. CD1B, THY1 and DOCK2 were found to be implicated in the metastatic recurrence of breast cancer. Conclusions Targeting macrophages or plasma cells may be new strategies for immunotherapy of breast cancer with brain metastases. THY1 and NEU2 may be potential therapeutic targets for breast cancer with brain metastases, and THY1, CD1B and DOCK2 may serve as potential prognostic markers for improvement of brain metastases survival.
- Published
- 2020
- Full Text
- View/download PDF